Androgenic Inactivation of FOXO1 in Prostate Cancer

前列腺癌中 FOXO1 的雄激素失活

• 批准号: 7313758
• 负责人: DONALD J. TINDALL
• 金额: $ 26.34万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7313758
• 关键词: 14-3-3 Proteins; Ablation; Affect; Androgen Receptor; Androgens; Attenuated; CDK2 gene; CDKN2A gene; Cancer Etiology; Cell Cycle; Cell Proliferation; Cell Survival; Cells; Cessation of life; Clinic; Cyclin-Dependent Kinase Inhibitor; DNA Damage; Data; Diagnosis; E2F Transcription Factor 1; EP300 gene; Growth; In Vitro; Invasive; Link; Malignant Neoplasms; Malignant neoplasm of prostate; Mediating; Molecular; Nuclear Export; Oxidative Stress; PTEN gene; Personal Satisfaction; Phosphorylation; Phosphorylation Inhibition; Play; Proliferating Cell Nuclear Antigen; Prostate; Proteins; Radiation; Radiation therapy; Research Personnel; Role; Second Primary Cancers; Serine; Signal Transduction; Testing; Therapeutic; Tumor Suppressor Proteins; United States; Withdrawal; Work; cancer cell; chemotherapeutic agent; forkhead protein; human CDK2 protein; in vivo; insight; irradiation; killings; knock-down; male; programs; tumor

DESCRIPTION (provided by applicant): Prostate cancer is the second leading cause of cancer death in the United States. Cancer cells in the prostate depend on androgens for growth and survival. Mitogenic effects of androgens have been linked to their modulation of cell cycle regulatory molecules such as cyclin-dependent kinase 2 and 4 (CDK2 and CDK4). However, the molecular mechanisms for androgen-mediated cell survival are not fully elucidated. We and others have shown that androgens promote prostate cancer survival by antagonizing the function of PTEN, a tumor suppressor protein. Further studies have revealed that androgens block PTEN signaling by directly inhibiting the function of the forkhead transcription factor FOXO1 (FKHR), a key downstream target of PTEN. Our preliminary data demonstrate that CDK2 interacts with and phosphorylates FOXO1 in vitro and in vivo. CDK2 inhibits the function of FOXO1 through phosphorylation of serine 249. Importantly, CDK2- mediated phosphorylation and inhibition of FOXO1 can be reversed upon DNA damage induced by chemotherapeutic agents and irradiation. In view of the roles of androgen-mediated proliferation and survival and the anti-tumor effect of the interaction between androgen ablation and radiation therapy in the clinic, we hypothesize that CDK2-mediated inactivation of FOXO1 plays an important role in androgen-stimulated proliferation, survival, and oxidative stress in prostate cancer cells. To test this hypothesis, we propose to determine (1) whether CDK2-mediated phosphorylation of FOXO1 plays an essential role in androgen- stimulated proliferation and survival of prostate cancer cells; (2) whether androgen-induced phosphorylation of FOXO1 inhibits FOXO1 transcriptional activity in prostate cancer cells; (3) whether activation of FOXO1 is a key factor that mediates the synergistic anti-tumor effect of androgen ablation and radiation therapy. The findings from this work will provide new insights into the working mechanisms of androgen-induced proliferation and survival of prostate cancer cells. Moreover, they should enhance our understanding of the underlying mechanisms of the therapeutic advantage of androgen ablation and radiation therapy in the clinic.

描述（由申请人提供）：前列腺癌是美国癌症死亡的第二大原因。前列腺癌细胞的生长和生存依赖于雄激素。雄激素的有丝分裂作用与它们对细胞周期调节分子（如周期蛋白依赖性激酶2和4 (CDK2和CDK4)）的调节有关。然而，雄激素介导的细胞存活的分子机制尚未完全阐明。我们和其他人已经证明雄激素通过拮抗PTEN（一种肿瘤抑制蛋白）的功能来促进前列腺癌的存活。进一步的研究发现雄激素通过直接抑制叉头转录因子FOXO1 （FKHR）的功能来阻断PTEN信号传导，叉头转录因子FOXO1是PTEN的关键下游靶点。我们的初步数据表明，CDK2在体外和体内与fox01相互作用并磷酸化fox01。CDK2通过磷酸化丝氨酸249抑制FOXO1的功能。重要的是，CDK2介导的磷酸化和FOXO1的抑制可以在化疗药物和照射引起的DNA损伤时逆转。鉴于雄激素介导的增殖和存活的作用，以及雄激素消融和放疗相互作用在临床中的抗肿瘤作用，我们假设cdk2介导的FOXO1失活在雄激素刺激的前列腺癌细胞增殖、存活和氧化应激中起重要作用。为了验证这一假设，我们提出要确定(1)cdk2介导的FOXO1磷酸化是否在雄激素刺激的前列腺癌细胞增殖和存活中起重要作用；(2)雄激素诱导的FOXO1磷酸化是否抑制前列腺癌细胞中FOXO1的转录活性；(3) FOXO1的激活是否介导雄激素消融与放疗协同抗肿瘤作用的关键因素。本研究结果将对雄激素诱导前列腺癌细胞增殖和存活的作用机制提供新的认识。此外，它们应该增强我们对雄激素消融和放射治疗在临床治疗优势的潜在机制的理解。